In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 179 for your search:
Drug:  imatinib mesylate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571AUS177, US177, RIGHT Trial, NCT00081926

2.

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 20 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BJP07, NCT00171977

3.

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571ACA09, NCT00171899

4.

Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT 2010-019189-94, NCT01297777

5.

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BIC08, NCT01172548

6.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARL/CT/13/001, NCT02103322

7.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 70
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CDR0000068089, NOVARTIS-CSTI5710106, FHCRC-1556.00, NCT00006343

8.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02372, S0033, INT-S0033, CDR0000068422, CAN-NCIC-S0033, CLB-80004, SWOG-S0033, E-S0033, N01CM17003, U10CA032102, NCT00009906

9.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2012-01862, CDR0000068859, COG-AALL0031, AALL0031, U10CA098543, NCT00022737

10.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02930, Z9001, CDR0000069452, U10CA076001, ACOSOG-Z9001, CAN-NCIC-SRC1, CALGB-ACOSOG-Z9001, SWOG-ACOSOG-Z9001, UWCC-UW-6303, UWCC-UW-03-8438-A-03, SRC1, NCT00041197

11.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: NCI, Other
Protocol IDs: CDR0000078099, E2993, MRC-LEUK-UKALL-XII, EST-4491, ECOG-2993, INT-0132, NCT00002514

12.

Phase: Phase III
Type: Treatment
Status: Unknown
Age: Any age
Sponsor: Other
Protocol IDs: III-MK-CML-IV, EU-20248, NCT00055874

13.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-62024, ISG-62024, FRE-FNCLCC-EORTC-62024, GEIS-EORTC-62024, 2004-001810-16, EUDRACT-2004-001810-16, NCT00103168

14.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SSGXVIII/AIO, NCT00116935

15.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BDE40, NCT00154375

16.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CECOG/GIST 1.2.001, CSTI571BIC07, NCT00293124

17.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00776, CDR0000482236, S0502, U10CA032102, U10CA180888, SWOG-S0502, CALGB-S0502, CAN-NCIC-S0502, NCT00324987

18.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CST1571BFR14, ET2002-021, NCT00367861

19.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2303, 2007-000208-34, NCT00471497

20.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-056, 2006-005712-27, NCT00481247

21.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3160A4-3000, B1871008, NCT00574873

22.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-62005, AGITG-AGO102-GIST, ISG-62005, SSG-15, NCT00685828

23.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2405, 2009-012616-40, NCT00760877

24.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107G2301, 2008-004758-34, NCT00785785

25.

Phase: Phase III
Type: Supportive care, Treatment
Status: Unknown
Age: 25 to 65
Sponsor: Other
Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617
1     
New Search